- 英文名称
- Tat-NR2B9c
- 分子式
- C105H188N42O30
- 分子量
- 2518.88
- 中文别名
- PSD95抑制剂(TAT-NR2B9C); H-TYR-GLY-ARG-LYS-LYS-ARG-ARG-GLN-ARG-ARG-ARG-LYS-LEU-SER-SER-ILE-GLU-SER-ASP-VAL-OH; TAT-NR2B9C/NA-1; 抑制剂多肽TAT-NR2B9C; YGRKKRRQRRRKLSSIESDV; (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,59S)-59-氨基-38-(3-氨基-3-氧代丙基)-26,47,50-三(4-氨基丁基)-14-((S)-仲丁基)-11-(2-羧乙基)-5-(羧甲基)-29,32,35,41,44,53-六(3-胍丙基)-8,17,20-三(羟甲基)-60-(4-羟基苯基)-23-异丁基-2-异丙基-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58-十九碳烷-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-十九碳氮杂六十碳酸; L-Tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-seryl-L-α-aspartyl-L-valine; Tat-NR2B9c/NA-1; (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,59S)-59-Amino-38-(3-amino-3-oxopropyl)-26,47,50-tris(4-aminobutyl)-14-((S)-sec-butyl)-11-(2-carboxyethyl)-5-(carboxymethyl)-29,32,35,41,44,53-hexakis(3-guanidinopropyl)-8,17,20-tris(hydroxymethyl)-60-(4-hydroxyphenyl)-23-isobutyl-2-isopropyl-4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58-nonadecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaazahexacontanoic acid; NA-1
- 用途
- PSD95的抑制剂,抑制PSD-95d2和PSD-95d1的EC50分别为6.7 nM和670 nM;扰乱PSD-95/NMDAR的相互作用,抑制PSD-95与NR2A、NR2B结合的IC50值分别为0.5 μM和8 μM;抑制神经元一氧化氮合酶(nNOS)/PSD-95相互作用,具有神经保护作用